首页> 外文期刊>Expert opinion on therapeutic targets >Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.
【24h】

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.

机译:克唑替尼用于EML4-ALK阳性肺腺癌:对于晚期疾病有希望吗? Kwak EL,Bang YJ,Camidge DR等人的评估。非小细胞肺癌的间变性淋巴瘤激酶抑制。 N Engl J Med 2010; 363(18):1693-703。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: In lung adenocarcinoma, certain mutations such as echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) are associated with lower sensitivity to chemotherapy, when used conventionally as the first-line therapy in the advanced stage of the disease. AREAS COVERED: This paper discusses the clinical and therapeutic importance of ALK mutations in NSCLC and the early clinical results of a Phase I study assessing crizotinib in patients with ALK mutations. EXPERT OPINION: Abnormal ALK is evolving as an important therapeutic target in patients with more aggressive lung adenocarcinoma. Further clinical studies are needed in order to assess if crizotinib, an ALK inhibitor, is able to increase the efficacy of the conventional chemotherapy in this disease subset.
机译:简介:在肺腺癌中,某些突变,例如棘皮动物微管相关蛋白样的4-间变性淋巴瘤激酶(ALK),在常规上用作疾病晚期的一线治疗时,对化疗的敏感性较低。涵盖的领域:本文讨论了NSCLC中ALK突变的临床和治疗重要性以及评估ALK突变患者克唑替尼的I期研究的早期临床结果。专家意见:ALK异常正在发展为更具侵略性的肺腺癌患者的重要治疗靶标。为了评估克唑替尼(一种ALK抑制剂)是否能够提高该疾病亚群中常规化疗的疗效,还需要进一步的临床研究。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号